<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610164</url>
  </required_header>
  <id_info>
    <org_study_id>SNAM18d.610</org_study_id>
    <nct_id>NCT04610164</nct_id>
  </id_info>
  <brief_title>The Effect of Tranexamic Acid (TXA) on Visualization During Shoulder Arthroscopy</brief_title>
  <official_title>The Effect of Tranexamic Acid on Visualization During Shoulder Arthroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rothman Institute Orthopaedics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rothman Institute Orthopaedics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid has seen an increase in use over the past decade in hip and knee arthroplasty&#xD;
      as well as spine surgery with more recent use seen in total shoulder arthroplasty (TSA). The&#xD;
      mechanism of action of TXA is as a lysine analogue that competitively inhibits the conversion&#xD;
      of plasminogen to plasmin thus resulting in its antifibrinolytic activity. Investigators have&#xD;
      showed that compared with placebo TXA had a statistically significant effect on blood and&#xD;
      postoperative hemoglobin levels in TSA. To date there are no studies investigating the effect&#xD;
      of TXA in arthroscopy of any kind or studies examining the ability of TXA to aid in surgeon&#xD;
      visualization in arthroscopic procedures. The investigators of this study will use change in&#xD;
      pump pressure as a surrogate objective measure for surgeon visualization. The hypothesis is&#xD;
      that participants who receive TXA will have a lower change in pump pressure compared to&#xD;
      participants who do not receive TXA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in operative factors</measure>
    <time_frame>2 hours</time_frame>
    <description>change in pump pressure (Î”P) during shoulder arthroscopy with a change in pump pressure of 15 mmHg set as the marker of surgeon visualization of the shoulder joint during surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>7 days</time_frame>
    <description>Investigators will be measuring whether there is a decrease in participants pain after surgery as assessed by visual analog score 7 days after surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Shoulder Arthroscopy</condition>
  <condition>Operative Bleeding</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group 1: TXA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive 1 gram intravenous TXA prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient will not receive TXA prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>Prior to surgery, the patient will receive 1 gram of IV TXA</description>
    <arm_group_label>Group 1: TXA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  participants aged 18-80&#xD;
&#xD;
          -  participants with an ASA (American Society of Anesthesiologists) score 1-3&#xD;
&#xD;
          -  participants with a surgical indication of full thickness small to massive rotator&#xD;
             cuff tear.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant females,&#xD;
&#xD;
          -  participants with a known allergy to tranexamic acid,&#xD;
&#xD;
          -  participants with active thromboembolic disease,&#xD;
&#xD;
          -  participants with seizure disorder,&#xD;
&#xD;
          -  participants with prior cerebrovascular accident (CVA),&#xD;
&#xD;
          -  history of cardiac stents or past history of thromboembolic disease,&#xD;
&#xD;
          -  presence of full-thickness subscapularis tear (&gt;50%),&#xD;
&#xD;
          -  participants with irreparable rotator cuff tears.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rothman Orthopaedic Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

